Exact Sciences FY2025 EPS Estimate Cut by Leerink Partnrs

Exact Sciences Corporation (NASDAQ:EXAS) – Equities research analysts at Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for shares of Exact Sciences in a report released on Wednesday, November 19th. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings of $0.04 per share for the year, down from their prior forecast of $0.42. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Exact Sciences’ current full-year earnings is ($0.58) per share. Leerink Partnrs also issued estimates for Exact Sciences’ Q4 2025 earnings at ($0.23) EPS.

Several other equities analysts also recently commented on EXAS. Wells Fargo & Company reiterated an “equal weight” rating and issued a $105.00 price objective (up previously from $85.00) on shares of Exact Sciences in a research note on Thursday. William Blair cut Exact Sciences from an “outperform” rating to a “market perform” rating in a research report on Thursday. Zacks Research raised Exact Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. TD Cowen boosted their price objective on Exact Sciences from $74.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Finally, BTIG Research downgraded shares of Exact Sciences from a “buy” rating to a “neutral” rating in a report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $79.38.

Exact Sciences Stock Up 0.2%

Exact Sciences stock opened at $100.90 on Monday. The firm has a 50 day moving average price of $62.85 and a 200-day moving average price of $55.47. The company has a quick ratio of 2.56, a current ratio of 2.89 and a debt-to-equity ratio of 0.94. Exact Sciences has a twelve month low of $38.81 and a twelve month high of $101.87. The company has a market capitalization of $19.12 billion, a P/E ratio of -18.58, a P/E/G ratio of 5.56 and a beta of 1.34.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.11. The business had revenue of $850.74 million during the quarter, compared to the consensus estimate of $810.42 million. Exact Sciences had a negative net margin of 34.19% and a negative return on equity of 1.75%. The firm’s quarterly revenue was up 20.0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.21) earnings per share. Exact Sciences has set its FY 2025 guidance at EPS.

Insiders Place Their Bets

In other news, Director James Edward Doyle sold 2,000 shares of the stock in a transaction dated Thursday, October 9th. The shares were sold at an average price of $60.00, for a total value of $120,000.00. Following the sale, the director directly owned 57,962 shares of the company’s stock, valued at approximately $3,477,720. This represents a 3.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Jacob A. Orville sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $75.00, for a total transaction of $375,000.00. Following the transaction, the executive vice president directly owned 23,237 shares of the company’s stock, valued at approximately $1,742,775. This represents a 17.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 9,858 shares of company stock worth $695,289 in the last quarter. 1.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. National Pension Service increased its holdings in shares of Exact Sciences by 75.1% in the first quarter. National Pension Service now owns 681 shares of the medical research company’s stock worth $29,000 after purchasing an additional 292 shares during the period. SVB Wealth LLC bought a new stake in Exact Sciences during the first quarter valued at $30,000. True Wealth Design LLC grew its position in Exact Sciences by 951.8% during the second quarter. True Wealth Design LLC now owns 589 shares of the medical research company’s stock worth $31,000 after buying an additional 533 shares in the last quarter. Westside Investment Management Inc. increased its stake in Exact Sciences by 100.0% in the 3rd quarter. Westside Investment Management Inc. now owns 542 shares of the medical research company’s stock worth $31,000 after acquiring an additional 271 shares during the last quarter. Finally, Country Trust Bank purchased a new stake in shares of Exact Sciences in the 2nd quarter valued at about $32,000. 88.82% of the stock is owned by institutional investors.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.